How does CAMBISeq work?
This innovative next-generation sequencing cancer test provides comprehensive insights into a patient’s cancer.
Unlock personalized cancer care. Book a Test Now
CAMBISeq utilizes an advanced technique called next-generation sequencing (NGS) to uncover the genetic mutations of a tumor by analysis of DNA and RNA to provide clinicians with important insights into cancer. It uses a patient’s genetic information to predict their response to targeted therapy, and immunotherapy. This test identifies variations in genes that our scientists use as biomarkers to assess sensitivity to different types of conventional therapies.
This innovative next-generation sequencing cancer test provides comprehensive insights into a patient’s cancer.
CAMBISeq utilizes a patient’s genetic information to assess the response to therapies like immunotherapy and targeted therapy for cancer. Comprehensive Genetic Analysis identifies variants in over 500 genes, detects fusions, and calculates tumor mutational burden (TMB) and microsatellite instability (MSI).
By pinpointing specific biomarkers, clinicians can tailor treatments for maximum effectiveness using personalized and targeted therapy options. Tumour Mutational Burden (TMB) is a quantitative genomic biomarker, which predicts sensitivity to checkpoint inhibitors.
Reserve your 30-minute free consultation
CAMBISeq empowers scientists and clinicians to decode genetic information by providing the Tumor Mutational Burden (TMB) score and Microsatellite Instability Status.
With this critical data, clinicians can tailor therapies to provide the most effective and personalized care.
Oncotrail has undergone rigorous evaluation to ensure high sensitivity and specificity, making it an invaluable tool for diagnostic purposes.
Through high-precision techniques, the test is used to monitor the effectiveness of a particular cancer treatment. This would objectively provide information on how well the treatment is going.
The non-invasive tracking of the cancer status would notify a treating physician whether to adjust current management or stay the course. This would be important to know in almost real-time rather than to find out much later that a treatment doesn't apply to a particular person.
Whole peripheral blood sample, Tissue, FFPE tissue
10-15 ml blood, minimum 400 mg tissue, minimum 100mg FFPE tissue
3-4 weeks in the lab
30 days after sample collection
Applicable for all cancer types
To whom it is relevant: The test is suitable for all patients with a confirmed cancer diagnosis.
A patient-centric revolution in cancer testing and monitoring. We are devoted to providing personalized tests designed with each patient’s unique genetic profile in mind.
©2024 All Rights Reserved. Designed by Bee High Media.